EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells-Reference-Cited by-同舟云学术

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells

Published:2019-01 Issue: Volume:39 Page:194-206
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Laurenzana Anna,Margheri Francesca,Biagioni Alessio^ORCID,Chillà Anastasia,Pimpinelli Nicola,Ruzzolini Jessica,Peppicelli Silvia,Andreucci Elena,Calorini Lido,Serratì Simona,Del Rosso Mario,Fibbi Gabriella

Funder

Associazione Italiana Ricerca sul Cancro

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference68 articles.

1. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

2. DTIC (NSC-45388) in malignant melanoma: a perspective;Comis;Cancer Treat Rep,1976

3. Management of cutaneous melanoma;Tsao;N Engl J Med,2004

4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999

5. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy;Rosenberg;Clin Cancer Res,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating network pharmacology and experimental models to investigate the efficacy and mechanism of Tiansha mixture on xerosis;Archives of Dermatological Research;2024-07-13

2. Unveiling the Role of Tryptophan 2,3-Dioxygenase in the Angiogenic Process;Pharmaceuticals;2024-04-27

3. Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation;Pharmaceutics;2024-04-11

4. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors;Frontiers in Immunology;2024-03-06

5. Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs;Pharmaceuticals;2023-10-09